BioPharmSignal logoBioPharmSignal

Biotech News

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsEarnings

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2,

Related news

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

URGNUroGen Pharma2026-10-27 22:00 EST

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Stock data

Close
9.37 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States